Shuang Xin
State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
Journal: Acta pharmacologica Sinica
Published: May 28, 2021
Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer.
Journal: Translational oncology
Published: August 18, 2020
Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
Journal: Journal of cancer research and clinical oncology
Published: March 18, 2020
The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study.
Journal: Annals of translational medicine
Published: February 12, 2020
Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients.
Journal: Journal of pharmaceutical and biomedical analysis
Published: February 01, 2019
Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.
Journal: The pharmacogenomics journal
Published: October 26, 2018
Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Journal: Cancer medicine
Published: July 02, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026